Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALL
Clinical trial NCT03559413 · COMPLETED
Trial details
- NCT number
- NCT03559413
- Sponsor
- University Children's Hospital Tuebingen
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-06-01
- Primary completion
- 2022-03-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.